RezoluteRZLT
RZLT
About: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Employees: 59
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
5,461% more call options, than puts
Call options by funds: $1M | Put options by funds: $18K
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
20% more funds holding
Funds holding: 59 [Q3] → 71 (+12) [Q4]
13% more capital invested
Capital invested by funds: $187M [Q3] → $212M (+$24.8M) [Q4]
4.98% more ownership
Funds ownership: 69.61% [Q3] → 74.59% (+4.98%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
133%
upside
Avg. target
$11.50
198%
upside
High target
$14
263%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 25% 1-year accuracy 42 / 171 met price target | 263%upside $14 | Buy Reiterated | 28 Apr 2025 |
JMP Securities Jason Butler 28% 1-year accuracy 11 / 40 met price target | 133%upside $9 | Market Outperform Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 5 articles about RZLT published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Rezolute, Inc. Announces Closing of Underwritten Offering
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the “Offering”) of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.
Positive
Benzinga
6 days ago
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Rezolute, Inc. RZLT on Wednesday announced the Independent Data Monitoring Committee's (DMC) recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital hyperinsulinism (HI) without increasing the study sample size.
Neutral
GlobeNewsWire
6 days ago
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of an underwritten offering, priced at-the-market under Nasdaq rules, of an aggregate of 20,786,923 shares of its common stock at an offering price of $3.25 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $90 million. Rezolute has also granted the underwriters a 30-day option to purchase up to an additional 4,153,846 shares of common stock at the offering price, less underwriting discounts and commissions.
Neutral
GlobeNewsWire
6 days ago
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. sites activated and enrolling patients REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc.
Positive
Zacks Investment Research
2 weeks ago
Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?
Rezolute (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute.
Positive
Zacks Investment Research
1 month ago
Here's Why Rezolute (RZLT) Looks Ripe for Bottom Fishing
Rezolute (RZLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Positive
Seeking Alpha
2 months ago
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses.
Neutral
GlobeNewsWire
2 months ago
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation
Positive
Zacks Investment Research
2 months ago
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
Charts implemented using Lightweight Charts™